TG Therapeutics Inc (STU:NKB2)
€ 15.004 -0.278 (-1.82%) Market Cap: 2.33 Bil Enterprise Value: 2.24 Bil PE Ratio: 74.36 PB Ratio: 15.79 GF Score: 73/100

TG Therapeutics Inc ULTIMATE I & II Phase 3 Investor & Analyst Webcast Transcript

Apr 16, 2021 / 12:30PM GMT
Release Date Price: €37.44 (-1.29%)
Operator

Ladies and gentlemen, thank you for standing by. Greetings, and welcome to the TG Therapeutics webinar.

(Operator Instructions)

As a reminder, this conference is being recorded. It's now my pleasure to turn the call over to Jenna Bosco. Please go ahead.

Jenna Bosco
TG Therapeutics, Inc. - VP of IR & Senior VP of Corporate Communications

Good morning, everyone, and thank you all for joining us. My name is Jenna Bosco, and I'm Head of Corporate communication for TG Therapeutics. And we're very excited to share with you all today a preview of the ULTIMATE I and II Phase III trial results.

Before we begin, I just want to remind everyone that we anticipate making some forward-looking statements based on our current expectations. These statements involve risks and uncertainties that can cause our actual results to differ materially. For a description of these risks and uncertainties, we encourage you to review the disclosures on this slide and also in our latest reports filed with the Securities and Exchange Commission and available

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot